Results 51 to 60 of about 24,744 (229)

Long-term results of transferring the patient from therapy with glucagon-like peptide-1 receptor agonists in combination with metformin to a dipeptidyl peptidase-4 inhibitor in combination with pioglitazone and inhibitor of type 2 sodium-glucose cotransporter in type 2 diabetes

Сахарный диабет
The pioglitazone belongs to the class of antidiabetic medications and has various pleiotropic effects. The evidence base for this medication, based on the results of randomized clinical trials, demonstrates convincing cardio- and cerebroprotective ...
V. V. Salukhov, D. A. Shipilova, A. A. Minakov   +2 more
doaj   +1 more source

Durability and Safety of Imeglimin as an Add‐On to DPP‐4 Inhibitors in Japanese Type 2 Diabetes: The 104‐Week FAMILIAR Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of imeglimin added to dipeptidyl peptidase‐4 (DPP‐4) inhibitors in Japanese patients with type 2 diabetes, focusing on glycemic durability and safety in elderly patients over 104 weeks. Materials and Methods This multicenter, randomized, placebo‐controlled trial comprised a 24‐week double ...
Masashi Shimoda, Takeshi Osonoi, Masahiro Iwamoto, Hideaki Kaneto, Kohei Kaku   +4 more
wiley   +1 more source

GLP‐1 Receptor Agonists and Risk of Skin Cancer in Adults With Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Existing evidence regarding the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and risk of melanoma and non‐melanoma skin cancer (NMSC) is inconclusive. This study aimed to assess the association between GLP‐1RA initiation and risks of melanoma and NMSC versus sodium–glucose cotransporter 2 inhibitors (SGLT2is ...
Huilin Tang, Bingyu Zhang, Ying Lu, Ting Zhou, Yiwen Lu, César A. Briceño, Jiali Han, Yong Chen   +7 more
wiley   +1 more source

Association Between Time in Range and Advanced Cardiovascular‐Kidney‐Metabolic Syndrome in Older Adults With Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiovascular, kidney and metabolic diseases are pathophysiologically interrelated and are conceptualised within the cardiovascular‐kidney‐metabolic (CKM) syndrome framework. However, evidence linking continuous glucose monitoring (CGM) to CKM syndrome remains limited.
Hang Su, Jiaying Ni, Jinghao Cai, Wei Zhu, Yufei Wang, Jian Zhou, Jingyi Lu, Xiaojing Ma   +7 more
wiley   +1 more source

Impact of Various Oral Hypoglycemic Agents on Hepatic Steatosis Reduction in MASLD and Type 2 Diabetes: Exploring the Bidirectional Relationship. A Narrative Review

Clinical Diabetology
OBJECTIVE: This review aims to explore the impact of various classes of oral hypoglycemic agents on hepatic steatosis reduction and liver functions in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D)
Emilia Kowalczyk, Iwona Gorczyca-Głowacka, Gerard Stupecki, Agnieszka Ciba-Stemplewska, Magdalena Dolecka-Ślusarczyk, Przemysław Wolak   +5 more
doaj   +1 more source

Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second‐Line Antidiabetic Drugs

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective To examine the effect of second‐line treatments (insulin secretagogues, thiazolidinediones, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors) on time to insulin initiation among patients with type 2 diabetes.
Ya‐Hui Yu, Qi Zhang, Estefania Zapata‐Bravo, Robert W. Platt, Pauline Reynier, Oriana H. Y. Yu, Kristian B. Filion   +6 more
wiley   +1 more source

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou, Christoforos K. Travlos, Lucas Lage Marinho, Thomas A. Mavrakanas, João Pedro Ferreira, Abhinav Sharma   +5 more
wiley   +1 more source

Noninsulin pharmacological management of type 1 diabetes mellitus

Indian Journal of Endocrinology and Metabolism, 2011
The injectable nature and other shortcomings of insulin have stimulated interest in studying the noninsulin pharmacological therapies to manage type 1 diabetes mellitus (T1DM).
Vishvas Garg
doaj   +1 more source

Association of Lipid Ratios With Cardiovascular Outcomes in Type 2 Diabetes: A Population Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To identify low‐ and high‐risk intervals for major adverse cardiovascular events (MACE) and all‐cause mortality according to lipid ratios in adults with Type 2 diabetes mellitus (T2DM), stratified by sex. Materials and Methods We used primary care electronic health records from the Spanish National Health Service including 303 199 adults ...
Enrique Carretero‐Anibarro, Jose Antonio Quesada, Manuel A. Ruiz‐Quintero, Didac Mauricio, Kamlesh Khunti, Domingo Orozco‐Beltrán   +5 more
wiley   +1 more source

Synthesis and in vitro antiproliferative and antibacterial activity of new thiazolidine-2,4-dione derivatives

Journal of Enzyme Inhibition and Medicinal Chemistry, 2018
In our present research, we synthesised new thiazolidine-2,4-diones (12–28). All the newly synthesised compounds were evaluated for antiproliferative and antibacterial activity.
Nazar Trotsko, Agata Przekora, Justyna Zalewska, Grażyna Ginalska, Agata Paneth, Monika Wujec   +5 more
doaj   +1 more source